DB17364InvestigationalCell transplant therapies
AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
- Mechanism
- Curator reviewed
Pharmacologically active on B-cell receptor CD22 and B-lymphocyte antigen CD19
- Also known as
- AUTO 3
Resolves to
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with AUTO3, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account